Healthy Subjects
Conditions
Brief summary
This is a single center prospective study. The purpose of this study is to assess the performance of FiberSense system across the glucose measurement ranges (from hypoglycemia to hyperglycemia) as compared with a gold standard reference laboratory method (YSI glucose) in healthy volunteers.
Detailed description
The FiberSense system is intended to be used by diabetic patients in a home use setting as a CGM system using the interstitial fluid (ISF) glucose as an indicator of blood glucose levels.The purpose of this study is to assess the performance of FiberSense system across the glucose measurement ranges (from hypoglycemia to hyperglycemia) as compared with a gold standard reference laboratory method (YSI glucose) in healthy volunteers.
Interventions
DEVICEFiberSense system
A novel CGM system based on a FiberSense system placed through the dermis of the patient.
Sponsors
Lee's Pharmaceutical Limited
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Intervention model description
For the first 10 subjects, all sensors will be removed after the end of the clamp measurement day. The last 2 subjects will continue to wear the three sensors after the clamp study. The second clamp study will take place at Day 7±1. After the second clamp study, the commercial CGM sensor will be removed. The two FiberSense sensors will be worn for up to Day 14.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Male or female age ≥ 18 years old. * Nondiabetic subjects with normal fasting plasma glucose and HbA1c (≤5.6%) * Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study. * Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices. * Willingness to abstain from bathing and swimming during their participation in the measurement phase. * In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate. * Written informed consent to participate in the study provided by the patient.
Exclusion criteria
* Currently pregnant, as demonstrated by a positive pregnancy test at screening and on day of first sensor insertion * Impaired hepatic function measured as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ three times the upper reference limit. * Impaired renal function measured as serum creatinine \> 1.2 times above the upper limit of normal. * Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study. * Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff. * Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device. * Extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis). * Have a known allergy to medical-grade adhesives, or known hypersensitivity to any of the products used in the study. * Known current or recent alcohol or drug abuse * Blood donation of more than 500 ml within the last three months * Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection. * History of epilepsy * History of cardiac arrhythmias * Clinically significant abnormality on ECG at screening * An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall performance of the FiberSense device as compared with YSI | 1 day | Proportion of FiberSense readings within ≤15% of the reference (YSI) reading for blood glucose levels \>100 mg/dl (5.55 mmol/l), and the proportion of FiberSense readings within ≤15 mg/dl (0.83 mmol/l) of the YSI reading for blood glucose levels ≤100 mg/dl. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean relative differences in FiberSense measured glucose from the reference laboratory standard (YSI) | 1 day | — |
| Mean Absolute Relative Differences in FiberSense measured glucose from the reference laboratory method (YSI) | 1 day | — |
| Accuracy of glucose rate of change measured by FiberSense sensor compared to glucose rate of change measured using the reference laboratory method (YSI) | 1 day | — |
| Lag time between FiberSense readings and reference laboratory method (YSI) results during induced glucose excursions | 1 day | — |
| Precision of FiberSense system readings: Precision Absolute Relative Differences with comparison of FiberSense system locations (inter and intra) | 1 day | — |
| Percentage of readings that are within 15% of the YSI values | 1 day | Comparisons of the percentage of readings from Dexcom and Fibersense, and comparisons of the percentage of readings from Bayer Contour Next and Fibersense, will be done separately during analysis. |
| Median Absolute Relative Differences in FiberSense measured glucose from the reference laboratory method (YSI) | 1 day | — |
| Percentage of readings that are within 30% of the YSI values | 1 day | Comparisons of the percentage of readings from Dexcom and Fibersense, and comparisons of the percentage of readings from Bayer Contour Next and Fibersense, will be done separately during analysis. |
| Percentage of readings that are within 40% of the YSI values | 1 day | Comparisons of the percentage of readings from Dexcom and Fibersense, and comparisons of the percentage of readings from Bayer Contour Next and Fibersense, will be done separately during analysis. |
| Percentage of readings that are greater than 40% of the YSI values | 1 day | Comparisons of the percentage of readings from Dexcom and Fibersense, and comparisons of the percentage of readings from Bayer Contour Next and Fibersense, will be done separately during analysis. |
| Adverse Event Reporting | 14 days | — |
| Median relative differences in FiberSense measured glucose from the reference laboratory standard (YSI) | 1 day | — |
| Percentage of readings that are within 20% of the YSI values | 1 day | Comparisons of the percentage of readings from Dexcom and Fibersense, and comparisons of the percentage of readings from Bayer Contour Next and Fibersense, will be done separately during analysis. |
Countries
Hong Kong
Outcome results
None listed